OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024. In the quarter to June 2026, revenue grew 244.2%, EPS grew 66.7% and free cash flow grew 211.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OABI
OmniAb, Inc. (OABI) EV/Sales
As of 16 October 2026, OmniAb, Inc. (OABI) trades at a EV/Sales of 14.0×. Over the past ten years it has ranged from 0.0× (December 2022) to 22.7× (April 2024); the current reading is higher than 81% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.4× | (27.10%) |
| FY2024 | 11.5× | (26.84%) |
| FY2023 | 15.7× | 346.10% |
| FY2022 | 3.5× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.9× | 30.88% |
| Mar 2026 | 5.3× | (37.12%) |
| Dec 2025 | 8.4× | 42.28% |
| Sep 2025 | 5.9× | (5.35%) |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 1.2× |
| MDXG MiMedx Group, Inc compare | 1.5× |
| GYRE Gyre Therapeutics, Inc. compare | 4.7× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.6× |
| OABI OmniAb, Inc. | 14.0× |
| ACHV Achieve Life Sciences, Inc. compare | 27.2× |
| CADL Candel Therapeutics, Inc. compare | 3,661× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)